Tirzepatide (Pen)

Description

Tirzepatide research pen — Canada

Researched & reviewed by the SPO Quality Team · Last reviewed: 2 October 2026

This listing is Tirzepatide in pen format (10mg, 20mg, 50mg or 60mg fill) — the same research material as our Tirzepatide vials, supplied in a pre-formatted research pen for laboratories that prefer logged, repeatable handling over loose vials. Tirzepatide (LY3298176) is a 39-amino-acid synthetic peptide carrying a C20 fatty-diacid chain, built to activate both the GIP and GLP-1 receptors^[1]. Laboratory research only; the pen is a handling format, not an instruction.

Identity at a glance

Batch documentation: a batch-specific COA for the Tirzepatide pen has not been posted yet — see the COA library. Reports for the vial listings, where posted, are on those pages.

What researchers have looked at

• First human data (2018): a 26-week phase 2 trial in type 2 diabetes compared LY3298176 with placebo and with dulaglutide and recorded glycaemic and body-weight endpoints^[2].
• Receptor pharmacology (2020): in cell assays it behaved as an imbalanced agonist — close to native GIP at the GIP receptor, weaker and biased toward cAMP at the GLP-1 receptor^[3].
• Structure (2022): cryo-EM structures of tirzepatide bound to GIPR and GLP-1R showed how its sequence and lipid chain set that different engagement of the two receptors^[4].
• Weight-management programme (2023): the US FDA cleared tirzepatide under the brand Zepbound for chronic weight management, a decision reported in JAMA^[5].

Regulatory status: tirzepatide is licensed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management) in the USA and elsewhere, and Health Canada lists both as prescription drugs. Those approvals cover Eli Lilly’s finished medicines and say nothing about research-grade powder.

Storage and handling

• Follow the label: keep the pen cool, dry and out of light, and do not subject it to repeated freeze–thaw.
• Log the batch number and dates of receipt and first use, as with any research material. No protocol or administration information is provided here.

Vial strengths: TIRZEPATIDE 10MG · TIRZEPATIDE 20MG · TIRZEPATIDE 50MG · TIRZEPATIDE 60MG. Other pens are on the peptide pens page; the whole range is on our buy peptides online in Canada page. Canada Post from inside Canada (shipping policy).

Frequently asked questions

What is the Tirzepatide pen?

The same synthetic Tirzepatide supplied in a pre-formatted research pen rather than a loose vial, for laboratories that want repeatable, logged handling. It is a research format only; no administration guidance of any kind is given.

Is there a batch report for the Tirzepatide pen?

Not yet. No batch-specific report for the pen is posted in the COA library. The page will state the report when one exists.

Is the Tirzepatide pen for human use?

No. The pen is supplied for laboratory research only and is not for human or animal use. No dosing, administration or protocol information is provided.

Cited

1. Coskun et al. (2018), Molecular metabolism — PMID 30473097
2. Frias et al. (2018), Lancet (London, England) — PMID 30293770
3. Willard et al. (2020), JCI insight — PMID 32730231
4. Sun et al. (2022), Proceedings of the National Academy of Sciences of the United States of America — PMID 35333651
5. Abbasi (2023), JAMA — PMID 37966831

For laboratory research use only. Not for human or animal consumption. No dosing, administration or protocol information is provided, and nothing here is a claim of efficacy or safety in humans.